These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 38465573)

  • 41. Τ cell-mediated adaptive immunity in the transition from metabolic dysfunction-associated steatohepatitis to hepatocellular carcinoma.
    Papadopoulos G; Giannousi E; Avdi AP; Velliou RI; Nikolakopoulou P; Chatzigeorgiou A
    Front Cell Dev Biol; 2024; 12():1343806. PubMed ID: 38774646
    [TBL] [Abstract][Full Text] [Related]  

  • 42. NIS2+
    Ratziu V; Harrison SA; Hajji Y; Magnanensi J; Petit S; Majd Z; Delecroix E; Rosenquist C; Hum D; Staels B; Anstee QM; Sanyal AJ
    J Hepatol; 2024 Feb; 80(2):209-219. PubMed ID: 38061448
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Metabolic Dysfunction-Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options.
    Portincasa P; Khalil M; Mahdi L; Perniola V; Idone V; Graziani A; Baffy G; Di Ciaula A
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891828
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
    Huttasch M; Roden M; Kahl S
    Metabolism; 2024 Aug; 157():155937. PubMed ID: 38782182
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Incretin-based investigational therapies for the treatment of MASLD/MASH.
    Brouwers B; Rao G; Tang Y; Rodríguez Á; Glass LC; Hartman ML
    Diabetes Res Clin Pract; 2024 May; 211():111675. PubMed ID: 38636848
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Metabolic dysfunction-associated steatotic liver disease and diabetes: the cross-talk between hepatologist and diabetologist.
    Yeh ML; Huang JF; Dai CY; Huang CF; Yu ML; Chuang WL
    Expert Rev Gastroenterol Hepatol; 2024 Aug; 18(8):431-439. PubMed ID: 39099428
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Metabolic disease and the liver: A review.
    Vargas M; Cardoso Toniasso SC; Riedel PG; Baldin CP; Dos Reis FL; Pereira RM; Brum MCB; Joveleviths D; Alvares-da-Silva MR
    World J Hepatol; 2024 Jan; 16(1):33-40. PubMed ID: 38313243
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Natural history of metabolic dysfunction-associated steatotic liver disease.
    Lekakis V; Papatheodoridis GV
    Eur J Intern Med; 2024 Apr; 122():3-10. PubMed ID: 37940495
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Defining an approach for therapeutic strategies in metabolic dysfunction-associated steatotic liver disease after liver transplantation.
    Siddiqui MS; Muthiah M; Satapathy SK; Patidar KR; Bhat M; Brandman D; Watt KD; Rinella M
    Hepatology; 2023 Dec; ():. PubMed ID: 38088872
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation.
    Kjærgaard K; Daugaard Mikkelsen AC; Landau AM; Eriksen PL; Hamilton-Dutoit S; Magnusson NE; Thomsen MB; Chen F; Vilstrup H; Mookerjee RP; Bay-Richter C; Thomsen KL
    JHEP Rep; 2024 Mar; 6(3):100992. PubMed ID: 38415019
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The first MASH drug therapy on the horizon: Current perspectives of resmetirom.
    Petta S; Targher G; Romeo S; Pajvani UB; Zheng MH; Aghemo A; Valenti LVC
    Liver Int; 2024 Jul; 44(7):1526-1536. PubMed ID: 38578141
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Drug-Induced Fatty Liver Disease (DIFLD): A Comprehensive Analysis of Clinical, Biochemical, and Histopathological Data for Mechanisms Identification and Consistency with Current Adverse Outcome Pathways.
    López-Pascual E; Rienda I; Perez-Rojas J; Rapisarda A; Garcia-Llorens G; Jover R; Castell JV
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791241
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Probiotic Mixture Ameliorates a Diet-Induced MASLD/MASH Murine Model through the Regulation of Hepatic Lipid Metabolism and the Gut Microbiome.
    Zhang F; Lo EKK; Chen J; Wang K; Felicianna ; Ismaiah MJ; Leung HKM; Zhao D; Lee JC; El-Nezami H
    J Agric Food Chem; 2024 Apr; 72(15):8536-8549. PubMed ID: 38575146
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings.
    Lee CM; Yoon EL; Kim M; Kang BK; Cho S; Nah EH; Jun DW
    Hepatology; 2024 Jun; 79(6):1393-1400. PubMed ID: 38100294
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role and therapeutic perspectives of extracellular vesicles derived from liver and adipose tissue in metabolic dysfunction-associated steatotic liver disease.
    Li W; Yu L
    Artif Cells Nanomed Biotechnol; 2024 Dec; 52(1):355-369. PubMed ID: 38833340
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice.
    Zou Z; Liu X; Yu J; Ban T; Zhang Z; Wang P; Huang R; Zheng F; Chang Y; Peng W; Tang Y; Feng X; Zhao Z; Lv X; Huang S; Guo J; Tuo Y; Zhou Z; Liang S
    J Hepatol; 2024 Jun; 80(6):834-845. PubMed ID: 38331323
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Manifestation and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease in a Predominately African American Population at a Multi-Specialty Healthcare Organization.
    Saini A; Rutledge B; Damughatla AR; Rasheed M; Naylor P; Mutchnick M
    Healthcare (Basel); 2024 Jul; 12(15):. PubMed ID: 39120181
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?
    Staufer K; Stauber RE
    Biomedicines; 2023 Jul; 11(8):. PubMed ID: 37626604
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Incident cardiac arrhythmias associated with metabolic dysfunction-associated steatotic liver disease: a nationwide histology cohort study.
    Simon TG; Ebrahimi F; Roelstraete B; Hagström H; Sundström J; Ludvigsson JF
    Cardiovasc Diabetol; 2023 Dec; 22(1):343. PubMed ID: 38093277
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Polymorphisms Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease Influence the Progression of End-Stage Liver Disease.
    Kocas-Kilicarslan ZN; Cetin Z; Faccioli LAP; Motomura T; Amirneni S; Diaz-Aragon R; Florentino RM; Sun Y; Pla-Palacin I; Xia M; Miedel MT; Kurihara T; Hu Z; Ostrowska A; Wang Z; Constantine R; Li A; Taylor DL; Behari J; Soto-Gutierrez A; Tafaleng EN
    Gastro Hep Adv; 2024; 3(1):67-77. PubMed ID: 38292457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.